The RSVPed Team is led by Johns Hopkins Bloomberg School of Public Health Professor and CIR Director Dr. Ruth A. Karron. The team conducts early stage clinical trials for vaccines against respiratory syncytial virus (RSV), the leading global cause of severe respiratory illness in infants and children. Dr. Karron also conduct studies in collaboration with investigators at JHSPH and at other institutions to assess factors that may contribute to the burden of RSV in low and middle income countries (LMICs). Learn more about these studies by clicking on the link below.
SARS-CoV-2 Epidemiology And Response in Children (SEARCh) is a prospective longitudinal household cohort study of Coronavirus Disease 2019 (COVID-19) infection and immune response in households with very young children.
Respiratory syncytial virus (RSV) is the most important global cause of viral acute lower respiratory tract illness (ALRI) in infants and children. In the United States, approximately 150,000 infants are hospitalized each year with RSV pneumonia or bronchiolitis (inflammation of the small airways), and up to 2 million children under the age of 5 receive medical care for RSV infection. Globally, RSV is estimated to cause up to 34 million cases of ALRI and up to 234,000 deaths in children each year.